KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) Return on Sales (2019 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Return on Sales for 7 consecutive years, with 201.37% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales fell 20140.0% year-over-year to 201.37%, compared with a TTM value of 1.4% through Dec 2025, up 138.0%, and an annual FY2025 reading of 66.33%, down 6635.0% over the prior year.
  • Return on Sales was 201.37% for Q4 2025 at Aurinia Pharmaceuticals, down from 0.43% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.43% in Q3 2025 and bottomed at 201.37% in Q4 2025.
  • Average Return on Sales over 5 years is 13.66%, with a median of 0.44% recorded in 2023.
  • The sharpest move saw Return on Sales surged 144985bps in 2021, then crashed -20140bps in 2025.
  • Year by year, Return on Sales stood at 1.42% in 2021, then skyrocketed by 36bps to 0.91% in 2022, then soared by 35bps to 0.6% in 2023, then surged by 104bps to 0.02% in 2024, then crashed by -816312bps to 201.37% in 2025.
  • Business Quant data shows Return on Sales for AUPH at 201.37% in Q4 2025, 0.43% in Q3 2025, and 0.31% in Q2 2025.